REMARKS

In the specification, Table 3 has been amended to correct an obvious error in the sequence identified as the sequence of CDR3 of clone L32. The amino acid sequence of SEQ ID NO:4, which is an obvious typographical error, has been replaced with the amino acid sequence of SEQ ID NO:2. Additionally, the amino acid sequence length of the sequence of CDR3 of clone L32 has been amended from 8 amino acids, which reflected the length of erroneously listed SEQ ID NO:4, to 6 amino acids, which properly reflects the length of SEQ ID NO:2.

CDR3 of clone L32 is properly taught as SEQ ID NO:2 in lines 2 and 7 of paragraph 100 of the specification as "a first hypervariable region (CDR3) of SEQ ID NO:2." Further, in paragraph 99, Applicants describe each heavy or light chain as having "a first, second, and third hypervariable region, which are CDR3, CDR2, and CDR1, respectively." As such, in paragraph 100, Applicants have properly described SEQ ID NO:2 as the "first hypervariable region" (denoted as CDR3) and expressly described SEQ ID NO:2 as CDR3.

Further support for SEQ ID NO:2 as CDR3 of the L32 clone is found, for example, in paragraph 85 on page 21 of the specification in conjunction with the sequence listing of the specification. In paragraph 85, SEQ ID NO:1 is described as the scFv fragment designated L32. A review of SEQ ID NO:1 in the sequence listing of the specification (in conjunction with SEQ ID NOS: 2-4, designated by Applicants as CDRs within SEQ ID NO:1) reveals SEQ ID NO:4 (designated by Applicants as CDR1) beginning at position 53 and SEQ ID NO:3 (designated by Applicants as CDR2) beginning at position 75. As would be expected, further review of SEQ ID NO:1 reveals SEQ ID NO:2 (designated by Applicants as CDR3) beginning at position 124. It is obvious, therefore, that CDR3 is located within the disclosed scFV fragment of the L32 clone (SEQ ID NO:1) beginning at position 124 of the sequence. It is further obvious that the CDR3 sequence within SEQ ID NO:1 corresponds to SEQ ID NO:2.

As a result, it is obvious that Applicants inadvertently included the sequence of SEQ ID NO:4 as CDR3 of clone L32 (scFV fragment SEQ ID NO:1) in Table 3. Applicants, therefore, have amended Table 3 to include SEQ ID NO:2 as CDR3 rather than SEQ ID NO:4. Applicants respectfully request the Examiner enter this amendment.

Response to Restriction Requirement of October 4, 2006

The Examiner has imposed a restriction requirement on the claims as set forth in the Restriction Requirement mailed October 4, 2006. Applicants set forth their election of Group I and relevant species under Group I below.

Election of Group I for Further Prosecution

The Examiner has restricted the presently pending claims in the above-captioned application into 7 groups:

Group I (claims 1-33, 46-48, 82-83 and 85), according to the Examiner, is drawn to PSGL-1-specific antibodies and composition/kits thereof;

Group II (claims 34-38), according to the Examiner, is drawn to isolated epitopes;

Group III (claims 39-45), according to the Examiner, is drawn to nucleic acids encoding PSGL-1-specific antibodies, vectors, host cells and methods of producing an antibody;

Group IV (claims 46-69), according to the Examiner, is drawn to methods of administering PSGL-1-specific antibodies;

Group V (claims 70-77), according to the Examiner, is drawn to methods of purging tumor cells with PSGL-1-specific antibodies;

Group VI (claims 78-79), according to the Examiner, is drawn to methods of diagnosing or staging a disease with PSGL-1-specific antibodies ex vivo; and

Group VII (claim 84), according to the Examiner, is drawn to methods of producing an antibody via a phage display library.

Applicants respectfully note that claims 80 and 81 have yet to be assigned a group by the Examiner.

Applicants wish to elect Group I:

Group I: Claims 1-33, 46-48, 82-83 and 85, which according to the Examiner, are drawn to PSGL-1-specific antibodies and composition / kits thereof, classified

in Class 424, subclass 130.1,; Class 435, subclass 810; and, Class 530, subclass 387.1.

Required Election of Species

The Examiner has further required election of a species from within Group I for further prosecution. The Examiner states that "[u]pon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141."

The Examiner has required Applicants to elect among (A) PSGL-1-specific antibodies that are not conjugated or complexed with an agent and (B) PSGL-1-specific antibodies that are conjugated or complexed with an agent as set forth in claims 19 through 31. The Examiner has further required Applicants to elect one particular antibody that binds PSGL-1 and to provide, for the Examiner's information, the heavy chain CDR SEQ ID NOs. and an epitope from among claims 1 through 18 that corresponds with the elected antibody.

Applicants elect for initial prosecution (understanding that upon the allowability of the elected species non-elected species will be rejoined for further examination) Species A:

Species A: PSGL-1-specific antibody not conjugated or complexed with an agent.

Applicants additionally elect for initial prosecution an antibody comprising SEQ ID NO:1. Within an antibody comprising SEQ ID NO:1, Applicants identify, as requested by the Examiner, the following heavy chain hypervariable regions: CDR1 (SEQ ID NO:4); CDR2 (SEQ ID NO:3); and, CDR3 (SEQ ID NO:2). Applicants further identify, as requested by the Examiner, an epitope (as claimed in claim 12) comprising at least one sulfated moiety.

Applicants make the foregoing elections and identifications with the understanding that upon the allowability of elected species, non-elected species will be further examined.

CONCLUSION

Applicants respectfully submit the claims are in condition for allowance. The Examiner is invited to contact the undersigned at 202.220.4258 to discuss any matter in this application.

The Commissioner is authorized to charge any fees relevant to this filing to Kenyon & Kenyon LLP's **Deposit Acct. No: 11-0600** including the fee related to the petition for extension of time contained herein.

Respectfully submitted,
KENYON & KENYON LLP

Date: 12/4/06

D. Clarke Reg. No. 42,210
FOR Teresa A. Lavenue
(Reg. No: 47,737)

1500 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 220-4258
Facsimile: (202) 220-4201